Schrödinger, Inc.
NASDAQ:SDGRMedical - Healthcare Information Services
+$0.00 today
- Market cap
- $1.79B
- Beta
- 1.64
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$1.40
Volume 1.18M
Average 1.35M
SDGR Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Schrödinger, Inc.NASDAQ: SDGR
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue growth accelerates
Q3 FY2026 revenue of $64.49M rose 18.7% year over year, ahead of the +4.8% change in trailing-twelve-month revenue. Sequentially, it rose 9.5% from the prior quarter. Over 3 fiscal years it compounded at +12.2% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $254.15M (-0.7%) for the fiscal year ending Dec 2026, a slowdown from the +23.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $64.49M+9.5% QoQ
- Last fiscal yearDec 2025
- $255.87M+23.3% YoY
- LTMSep 2026
- $269.2M+4.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +18.7% | -19.0% | -37.7 pp |
| 1 year | +23.3% | -0.7% | -24.0 pp |
| 3-year CAGR | +12.2% | +2.8% | -9.5 pp |
| 5-year CAGR | +9.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 255.87M USD
- Year-over-year change
- +23.3%
- 4-year CAGR
- +16.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 255.87M | +23.3% |
| FY2024 | 2024-12-31 | 207.54M | -4.2% |
| FY2023 | 2023-12-31 | 216.67M | +19.7% |
| FY2022 | 2022-12-31 | 180.96M | +31.2% |
| FY2021 | 2021-12-31 | 137.93M | — |
Revenue vs competitors
How SDGR compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +4.8% is the 6th highest of 8, against a peer median of +16.5%.
- Over three fiscal years its annual growth of +12.2% compares with a peer median of +10.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jul 2026 | $3.46B USD | +16.5% | +14.0% | |
| LTM Mar 2026 | $419.75M USD | +6.4% | +7.7% | |
| LTM Sep 2026 | $269.2M USD | +4.8% | +12.2% | |
| LTM Feb 2026 | $80.54M USD | +2.5% | +13.7% | |
| LTM Sep 2026 | $67.86M USD | +92.1% | -46.3% | |
GENBGenerate Biomedicines, Inc. | FY2025 | $31.89M USD | +55.9% | — |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$18.36M CAD | +3.3% | +8.2% |
| LTM Jun 2026 | $10.35M USD | +23.9% | +123.2% | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding SDGR) | — | +16.5% | +10.9% | |
Competitors are the stored peer set for SDGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 137.93M | 180.96M | 216.67M | 207.54M | 255.87M |
| Cost of Revenue | 72.31M | 79.93M | 75.97M | 75.46M | 113.26M |
| Gross Profit | 65.62M | 101.02M | 140.69M | 132.08M | 142.61M |
| Gross Margin | 47.6% | 55.8% | 64.9% | 63.6% | 55.7% |
| Research & Development | 90.9M | 126.37M | 181.77M | 201.79M | 173.14M |
| Selling, General & Admin | 86.16M | 121.47M | 136.37M | 139.59M | 136.37M |
| Operating Expenses | 177.06M | 247.84M | 318.14M | 341.38M | 309.51M |
| Depreciation & Amortization | 2.85M | 4.34M | 5.55M | 6.16M | 6.02M |
| EBITDA | (97.96M) | (144.78M) | 48.47M | (179.55M) | (96.3M) |
| EBITDA Margin | -71.0% | -80.0% | 22.4% | -86.5% | -37.6% |
| Operating Income | (111.44M) | (146.82M) | (177.45M) | (209.3M) | (166.9M) |
| Operating Margin | -80.8% | -81.1% | -81.9% | -100.8% | -65.2% |
| Interest Income | 1.06M | 3.95M | 0 | 0 | 0 |
| Interest Expense | 0 | 3K | 0 | 0 | 0 |
| Other Income / Expenses | 10.64M | (2.31M) | 220.37M | 23.59M | 64.57M |
| Income Before Tax | (100.81M) | (149.12M) | 42.92M | (185.71M) | (102.33M) |
| Pre-Tax Margin | -73.1% | -82.4% | 19.8% | -89.5% | -40.0% |
| Income Tax Expense | 411K | 63K | 2.2M | 1.41M | 939K |
| Net Income | (100.39M) | (149.19M) | 40.72M | (187.12M) | (103.27M) |
| Net Margin | -72.8% | -82.4% | 18.8% | -90.2% | -40.4% |
| EPS (Basic) | (1.43) | (2.10) | 0.57 | (2.57) | (1.41) |
| EPS (Diluted) | (1.43) | (2.10) | 0.54 | (2.57) | (1.41) |
| Weighted Avg Shares | 70.59M | 71.17M | 71.78M | 72.67M | 73.44M |
| Weighted Avg Shares (Diluted) | 70.59M | 71.17M | 74.99M | 72.67M | 73.44M |
Schrödinger, Inc.
NASDAQ:SDGR
Intrinsic Alpha fair value
Locked
Current Price
$27.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.